Victory Capital Management Inc. Sells 3,716 Shares of Repligen Co. (NASDAQ:RGEN)

Victory Capital Management Inc. decreased its position in Repligen Co. (NASDAQ:RGEN) by 27.3% during the fourth quarter, HoldingsChannel reports. The firm owned 9,908 shares of the biotechnology company’s stock after selling 3,716 shares during the quarter. Victory Capital Management Inc.’s holdings in Repligen were worth $1,426,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its position in Repligen by 4.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 377,900 shares of the biotechnology company’s stock worth $54,395,000 after acquiring an additional 14,521 shares during the period. NBW Capital LLC increased its position in Repligen by 19.7% during the fourth quarter. NBW Capital LLC now owns 25,194 shares of the biotechnology company’s stock worth $3,626,000 after acquiring an additional 4,152 shares during the period. Norden Group LLC boosted its stake in Repligen by 10.2% during the fourth quarter. Norden Group LLC now owns 3,698 shares of the biotechnology company’s stock worth $532,000 after buying an additional 341 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Repligen by 89.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,057 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 499 shares during the period. Finally, Nichols & Pratt Advisers LLP MA increased its holdings in Repligen by 11.1% in the 4th quarter. Nichols & Pratt Advisers LLP MA now owns 1,505 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 150 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 5.5 %

Shares of NASDAQ:RGEN opened at $144.34 on Wednesday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $200.23. The company’s 50-day moving average price is $156.98 and its two-hundred day moving average price is $148.49. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.09 billion, a P/E ratio of -283.02, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, research analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax bought 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RGEN. TD Cowen began coverage on shares of Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Royal Bank of Canada boosted their price target on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Finally, Evercore ISI began coverage on shares of Repligen in a report on Tuesday. They issued an “in-line” rating and a $155.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Repligen presently has an average rating of “Hold” and an average target price of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.